1. Home
  2. HIX vs CUVL Comparison

HIX vs CUVL Comparison

Compare HIX & CUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset High Income Fund II Inc.

HIX

Western Asset High Income Fund II Inc.

HOLD

Current Price

$3.48

Market Cap

351.3M

Sector

Finance

ML Signal

HOLD

Logo Clinuvel Pharmaceuticals Limited American Depositary Shares

CUVL

Clinuvel Pharmaceuticals Limited American Depositary Shares

HOLD

Current Price

$4.94

Market Cap

374.2M

Sector

Miscellaneous

ML Signal

HOLD

Company Overview

Basic Information
Metric
HIX
CUVL
Founded
1998
1999
Country
United States
Australia
Employees
N/A
16
Industry
Finance/Investors Services
Miscellaneous
Sector
Finance
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
351.3M
374.2M
IPO Year
1998
N/A

Fundamental Metrics

Financial Performance
Metric
HIX
CUVL
Price
$3.48
$4.94
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 365.5K
5.3K
Earning Date
01-01-0001
08-27-2026
Dividend Yield
★ 13.14%
0.56%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$0.47
Revenue Next Year
N/A
$6.25
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.34
$4.88
52 Week High
$4.33
$8.20

Technical Indicators

Market Signals
Indicator
HIX
CUVL
Relative Strength Index (RSI) 45.23 42.09
Support Level $3.46 $4.91
Resistance Level $4.04 $5.40
Average True Range (ATR) 0.04 0.19
MACD 0.01 0.02
Stochastic Oscillator 79.41 36.88

Price Performance

Historical Comparison
HIX
CUVL

About HIX Western Asset High Income Fund II Inc.

Western Asset High Income Fund II Inc is a diversified closed-end management investment company. Its primary investment objective is to maximize current income by investing at least 80% of its net assets, plus any borrowings for investment purposes, in high-yield debt securities. As a secondary objective, the Fund seeks capital appreciation to the extent consistent with its objective of seeking to maximize current income.

About CUVL Clinuvel Pharmaceuticals Limited American Depositary Shares

Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.

Share on Social Networks: